TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
−3.86%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.64
From 52W high−94.55%
Volume124401.00
Market cap$10.14M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.64
From 52W high
−94.55%
Volume
124401.00
Market cap
$10.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
34.1
MomentumView details →
1D Return
−3.86%
YTD Return
−78.38%
SummaryUpdated Jun 1, 2026
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage biotechnology company founded in 2011 and headquartered in South San Francisco, California. Originally established as a subsidiary of Inception Sciences, Inc., the company went public in November 2012. Tempest focuses on developing innovative small molecule therapeutics specifically designed to treat various forms of cancer, with a particular emphasis on targeting immune system pathways that can enhance the body's natural ability to fight tumors.
Similar companies
Latest newsMore news →
Tempest Therapeutics, Inc. Chief Financial Officer Nicholas Rossettos resigned, effective September 22, 2026.21d agoTempest Therapeutics, Inc. appointed Constance Ames as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective September 22, 2026.21d agoTempest Therapeutics, Inc. appointed Nancy Freda-Smith as a Class III director and member of its Audit Committee, effective September 22, 2026.21d ago